drugset
drugset / Trial / NCT01116843

Study to Assess Biomarkers in Patients With Resectable Oral Cavity Cancer Randomized to Receive Preoperative Treatment

NCT01116843 ↗

Phase 1/2 Completed 13 enrolled University Health Network, Toronto Pfizer · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The objective of this study is to assess the biological effects in the primary tumor following a short, pre-operative course of treatment with PF-00298804 in patients with Oral Cavity Cancer.

Timeline

Start
2010-05
Primary completion
2012-02
Completion
2014-02

Drugs

EvaluationDrugModalityDoseRoute
Subject DACOMITINIB ANHYDROUS Small molecule 45 mg Oral

Indications

oral cavity cancer